DiaMedica Therapeutics (NASDAQ:DMAC) Stock Price Down 2.3% – Should You Sell?

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) shares fell 2.3% during trading on Friday . The company traded as low as $8.13 and last traded at $8.16. 135,966 shares were traded during mid-day trading, a decline of 60% from the average session volume of 336,492 shares. The stock had previously closed at $8.35.

Wall Street Analyst Weigh In

Several brokerages have recently commented on DMAC. Wall Street Zen lowered DiaMedica Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, November 15th. Lake Street Capital restated a “buy” rating on shares of DiaMedica Therapeutics in a report on Monday, January 5th. Cowen initiated coverage on shares of DiaMedica Therapeutics in a research note on Thursday, October 30th. They set a “buy” rating for the company. Cantor Fitzgerald began coverage on shares of DiaMedica Therapeutics in a research note on Friday, November 14th. They issued an “overweight” rating on the stock. Finally, TD Cowen started coverage on shares of DiaMedica Therapeutics in a report on Thursday, October 30th. They issued a “buy” rating on the stock. Six investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $12.33.

DiaMedica Therapeutics Price Performance

The company’s 50 day moving average price is $7.94 and its 200 day moving average price is $6.48. The firm has a market cap of $424.97 million, a PE ratio of -11.49 and a beta of 1.15.

DiaMedica Therapeutics (NASDAQ:DMAC) last released its earnings results on Wednesday, November 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). Sell-side analysts expect that DiaMedica Therapeutics, Inc. will post -0.59 earnings per share for the current fiscal year.

Insider Buying and Selling at DiaMedica Therapeutics

In other news, major shareholder Jan Stahlberg acquired 73,099 shares of the firm’s stock in a transaction dated Tuesday, November 25th. The stock was acquired at an average cost of $8.57 per share, with a total value of $626,458.43. Following the transaction, the insider owned 8,825,742 shares in the company, valued at approximately $75,636,608.94. This trade represents a 0.84% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In the last quarter, insiders have acquired 1,061,277 shares of company stock valued at $7,632,627. 7.30% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On DiaMedica Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Cooperman Leon G increased its position in DiaMedica Therapeutics by 98.2% in the 3rd quarter. Cooperman Leon G now owns 3,269,761 shares of the company’s stock valued at $22,463,000 after acquiring an additional 1,619,761 shares during the period. Millennium Management LLC purchased a new position in shares of DiaMedica Therapeutics in the 3rd quarter valued at approximately $8,157,000. Paragon Associates & Paragon Associates II Joint Venture increased its holdings in shares of DiaMedica Therapeutics by 34.6% in the third quarter. Paragon Associates & Paragon Associates II Joint Venture now owns 875,000 shares of the company’s stock valued at $6,011,000 after purchasing an additional 225,000 shares during the period. Geode Capital Management LLC increased its holdings in shares of DiaMedica Therapeutics by 99.6% in the second quarter. Geode Capital Management LLC now owns 630,148 shares of the company’s stock valued at $2,458,000 after purchasing an additional 314,407 shares during the period. Finally, Royal Bank of Canada raised its stake in shares of DiaMedica Therapeutics by 46,879.1% during the first quarter. Royal Bank of Canada now owns 155,031 shares of the company’s stock worth $588,000 after purchasing an additional 154,701 shares during the last quarter. Hedge funds and other institutional investors own 10.12% of the company’s stock.

About DiaMedica Therapeutics

DiaMedica Therapeutics, Inc (NASDAQ: DMAC) is a clinical‐stage biopharmaceutical company focused on developing novel therapies for acute and chronic central nervous system conditions. The company’s lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to promote neuroprotection and tissue repair through modulation of the kallikrein‐kinin system. DiaMedica’s research and development efforts are centered on translating the regenerative potential of DM199 into effective treatments for disorders with high unmet medical need.

DM199 is being evaluated in acute ischemic stroke, where preclinical studies have demonstrated potential benefits in blood flow restoration, inflammation reduction and neuronal survival.